Sandler initially dismissed the idea of rapamycin as a longevity drug, but as he read up online, he decided there might be something to it and ordered a year’s supply for about $200 from a supplier in India.
Researchers have found that rapamycin can modify a kind of cellular communications system that gives cells certain directions — to grow when the body has plenty of food and to slow down when nutrients are scarce. The drug can dial down the signal to grow, causing cells to clear out accumulated junk and allowing them to run more efficiently.
Despite the buzz surrounding the drug, it is unlikely that the Food and Drug Administration will ever approve it for longevity. The agency doesn’t consider aging to be a disease, and rapamycin’s generic status means there’s little financial incentive to run expensive clinical trials to test it on age-related afflictions. So doctors and entrepreneurs are increasingly marketing rapamycin beyond the scope of its regulatory label, believing a potentially life-extending drug is effectively hiding in plain sight.